Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027

Pharma Leader Series: Top 30 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market Forecast 2017-2027

  • July 2017 •
  • 311 pages •
  • Report ID: 5089832 •
  • Format: PDF
North America, Europe, Japan, India, China, Other Leading Developed Market API Manufacturers, API Manufacturing, FDF Manufacturing

The global pharmaceutical contract manufacturing market was valued at $76.6bn in 2016 and is expected to grow at a CAGR of 6.6% in the first half of the forecast period. Between 2011 and 2016, the top 5 emerging market CMOs grew at a CAGR of 13.6%, whereas the leading developed market CMOs grew at a CAGR of 1.7% over the same period.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 311-page report you will receive 184 tables and 111 figures – all unavailable elsewhere.

The 311-page report provides clear detailed insight into the pharmaceutical CMOs market. Discover the key drivers and challenges affecting the market.

Report Scope

• Global Pharmaceutical Contract Manufacturing Market forecast from 2017-2027:
• API Manufacturing
• FDF Manufacturing
• Other Services

This report profiles 30 leading CMOs in North America, Europe, Japan, China and India:
• Catalent
• Patheon
• Baxter
• AbbVie
• Pfizer
• Lonza
• Evonik Degussa
• Royal DSM
• Boehringer Ingelheim
• Fareva
• Aenova
• Famar
• Vetter
• Almac
• Delpharm
• Siegfried
• Corden
• Recipharm
• Aesica
• Nipro
• Daito
• Teva API
• Esteve Quimica
• Euticals
• Zhejiang Hisun Pharmaceuticals
• Zhejiang Huahai Pharmaceuticals
• Shandong Xinhua Pharmaceuticals
• Aurobindo Pharma
• Divis Laboratories
• Dr. Reddy’s Laboratories

The content of each profile differs, depending on the organisation. In general, a profile gives the following information:

• Overview of the company’s contract manufacturing services and operations

• Analysis of recent financial performance – annual revenue for CMO services, including some data on operating profit and margins

• Assessment of developments – activities, acquisitions, production capacity, deals, new service offerings and collaborations

• SWOT analysis – a firm’s strengths and weaknesses, as well as opportunities and threats to manufacturing sales growth from 2016 onwards

• Forecasting of pharmaceutical manufacturing revenue to 2027, as well as projected operating profit and margin for some companies.